NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NA
Post# of 375
(Total Views: 199)
Posted On: 04/03/2023 4:47:33 PM
NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces FY 2022 Results, Corporate Update
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today released its financial results for the full year ended Dec. 31, 2022. The company also provided a clinical update of its anti-cancer drug candidate currently in development for the treatment of primary and metastatic brain and CNS cancer. “Over the course of 2022, we made significant advancements in our ongoing clinical trial for Berubicin. We have expanded our clinical trial sites across Europe and continued with an encouraging and increasingly rapid pace of enrollment. As it currently stands, we are on track to reach our pre-planned interim analysis during the third quarter of 2023. We remain laser focused on moving this trial toward the finish line and importantly, potentially address the significant unmet need that currently exists for the treatment of GBM,” said John Climaco, CEO of CNS Pharmaceuticals. “We are incredibly grateful to all stakeholders including our clinical staff for the continued support and execution. We believe 2023 is poised to be the most important year for the company to-date, and we continue to focus on the operational execution that will deliver the potential value-driving milestones in the near term.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today released its financial results for the full year ended Dec. 31, 2022. The company also provided a clinical update of its anti-cancer drug candidate currently in development for the treatment of primary and metastatic brain and CNS cancer. “Over the course of 2022, we made significant advancements in our ongoing clinical trial for Berubicin. We have expanded our clinical trial sites across Europe and continued with an encouraging and increasingly rapid pace of enrollment. As it currently stands, we are on track to reach our pre-planned interim analysis during the third quarter of 2023. We remain laser focused on moving this trial toward the finish line and importantly, potentially address the significant unmet need that currently exists for the treatment of GBM,” said John Climaco, CEO of CNS Pharmaceuticals. “We are incredibly grateful to all stakeholders including our clinical staff for the continued support and execution. We believe 2023 is poised to be the most important year for the company to-date, and we continue to focus on the operational execution that will deliver the potential value-driving milestones in the near term.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)